近一年，QDII产品的业绩呈现明显分化。据统计，截至12月17日，排名首位的汇添富香港优势精选混 合A净值涨幅为111%，领先排名末位的产品124.6个百分点。受益于港股创新药整体涨幅较大，相关产 品在QDII基金业绩榜上排名居前。相较之下，沙特主题ETF和原油类产品近一年则普遍表现疲软，位列 排行榜尾端。 Choice数据显示，截至12月17日，QDII基金近一年净值平均上涨20.9%。其中，汇添富香港优势精选混 合A以111%的净值涨幅排名首位，紧随其后的是创金合信全球医药生物股票发起A、广发中证香港创新 药，净值涨幅分别为86.54%、74.14%。此外，易方达全球医药行业混合、南方港股医药行业混合发起 A、华夏恒生生物科技ETF等产品近一年净值涨幅均超过60%。 从QDII基金业绩排行榜来看，前十位主要是港股基金，其中不少产品重仓了港股医药板块。以汇添富 香港优势精选混合A为例，截至三季度末，基金前五大重仓股分别是映恩生物-B、科伦博泰生物-B、信 达生物、三生制药和康诺亚-B。而易方达全球医药行业混合前五大重仓股分别为复宏汉霖、信达生物、 科伦博泰生物-B、映恩生物-B和乐普生物-B。 （文章来源： ...

Core Insights - The article discusses the recovery of actively managed equity funds in 2023, highlighting the turnaround of previously underperforming funds known as "four毛基" and "five毛基" [1][2]. Group 1: Fund Performance - Several funds, including Hengyue Advantage Selection and Huatai Bairui Quality Selection, have successfully increased their net asset values (NAV) from below 0.6 yuan to above 1 yuan due to strong performance in 2023 [3]. - Hengyue Advantage Selection achieved the highest increase, with a year-to-date growth of 146.87%, rising from 0.60 yuan to 1.47 yuan [3]. - The funds that performed well were heavily invested in sectors like artificial intelligence and storage chips, which saw significant demand growth [3][5]. Group 2: Investment Strategies - Some funds maintained their positions in sectors like optical modules and computing power, benefiting from the market recovery [2][5]. - Other funds, such as Fangzheng Fubon Xinhong, changed their investment strategies, shifting focus to humanoid robotics, which led to substantial NAV increases [5]. - The article notes that funds that were initially launched during high market periods (2020-2021) faced challenges but adapted their strategies to capitalize on emerging trends [4][6]. Group 3: Redemption Trends - Despite the recovery in NAV, many funds did not see a corresponding increase in share volume, as investors often chose to redeem their shares once they broke even [2][6]. - Historical data indicates that the probability of redemption is highest when funds return to their original investment levels, leading to significant outflows from several funds [6]. - In the third quarter, there was a net redemption of 220 billion shares from equity funds, marking the largest single-quarter redemption in recent years [6]. Group 4: Ongoing Challenges - Not all funds that were previously underperforming managed to rebound, with some still trading below 0.5 yuan [7]. - Certain sectors, such as consumer and military industries, did not perform well even in a rising market, leading to continued underperformance for funds heavily invested in these areas [7].

Core Insights - The QDII funds market has shown strong performance in the first ten months of the year, with 95.1% of the 650 comparable funds reporting net value increases, while only 32 funds experienced declines [1] Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hong Kong Advantage Selected Mixed A and C, both achieving returns of 117.54% and 117.53% respectively [1] - A total of 10 QDII funds recorded gains exceeding 78%, with E Fund's Global Growth Selected Mixed A and C (USD and RMB) each surpassing 83% [2][3] - The leading funds in the innovation drug sector have significantly contributed to the overall performance, with notable funds like the GF CSI Hong Kong Innovation Drug ETF and others achieving returns between 78.11% and 88.09% [3] Investment Focus - The investment strategy of the top-performing funds emphasizes sectors such as innovative pharmaceuticals and high-barrier medical equipment, targeting companies with global competitiveness and growth potential [1][3] - The top holdings of the leading funds include major players in the biotech and pharmaceutical industries, such as TSMC, NVIDIA, and Alibaba [2][3] Market Trends - The innovation drug sector has rebounded, leading to a broad increase in related stocks, which has positively impacted the performance of funds heavily invested in this area [1][3] - Conversely, funds focused on oil and gas, as well as real estate, have underperformed, indicating a sector rotation within the QDII market [4]

Core Insights - In the first three quarters of this year, 624 out of 650 comparable QDII funds saw an increase in net value, representing a 96% success rate, while 26 funds experienced a decline [1] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers achieving returns exceeding 155% [1][2] - The top-performing QDII funds include Huatai-PB Hong Kong Advantage Selected Mixed Fund A and C, both achieving returns of 155.14% and 155.09% respectively [1] Fund Performance - 13 QDII funds recorded gains over 100%, with four from E Fund Management, including E Fund Global Pharmaceutical Industry Mixed Fund A and C, all surpassing 102% [2] - The top holdings of these funds include companies like Innovent Biologics, I-Mab Biopharma, and others in the innovative drug sector [2][3] - Other notable funds with over 100% returns include GF CSI Hong Kong Innovative Drug ETF and ICBC New Economy Mixed Fund, with respective gains of 112.80% and 104.12% [3] Fund Management - The current fund manager for Huatai-PB Hong Kong Advantage Selected Mixed Fund is Zhang Wei, who has extensive experience in the pharmaceutical sector [2] - E Fund's funds are managed by Yang Zhenxiao, who has a background in investment management and industry research [3] Sector Analysis - The innovative drug sector has shown strong performance, contributing to the significant gains of various QDII funds [3][4] - Funds with poor performance are primarily those focused on real estate and oil & gas sectors, as well as those tracking the S&P 500 healthcare index [5]

Core Viewpoint - The A-share and Hong Kong stock markets have shown a continuous upward trend since mid-April, achieving new highs in the third quarter, with equity funds yielding significant returns [1] Group 1: Active Equity Funds - A total of 37 funds have doubled their returns this year as of September 26, with 31 active equity funds in A-shares achieving over 100% returns [2][4] - The average return for active equity funds is 30.32%, with over 98% of these funds reporting positive returns [4] - The top-performing fund, Yongying Technology Smart Selection A, has a return rate of 189.58%, significantly boosted by its focus on AI concept stocks [4][6] Group 2: Passive Index Funds - Nearly 98% of index funds have achieved positive returns, with an average return of 27.53% [7] - Funds tracking innovative drugs, communications, and artificial intelligence have outperformed, with the top two funds yielding returns of 103.96% and 100.59% [7] - Underperforming index funds are primarily those tracking energy, food and beverage, and coal sectors, with losses exceeding 5% [7] Group 3: QDII Funds - QDII funds focused on the Hong Kong market, particularly in innovative drug assets, have performed well, with four funds exceeding 100% returns [3][8] - The top-performing QDII fund, Huatai Bairui Hang Seng Innovation Drug ETF, has a return of 152.25% [8] - Other notable funds in this category have also shown strong performance, with several exceeding 90% returns [8]

Group 1 - The Hong Kong stock market showed strong performance last week, with the Hang Seng Index surpassing 27,000 points for the first time in nearly four years, driven primarily by the technology sector, which saw a weekly increase of 5.09% in the Hang Seng Tech Index [1] - Significant capital inflows were observed in Hong Kong-related ETFs, with the E Fund Hang Seng Tech ETF receiving over 800 million yuan in net inflows, bringing its total size to 20.45 billion yuan [1] - Other ETFs, such as the GF Hang Seng Tech ETF and the Huaxia Hang Seng Internet Technology ETF, also experienced substantial net inflows exceeding 600 million yuan, indicating strong investor confidence in the Hong Kong tech sector [1] Group 2 - Southbound capital has played a crucial role in the recent recovery of the Hong Kong stock market, with ETFs focused on technology and internet sectors seeing significant net inflows, providing stable liquidity support [2] - Multiple public fund institutions are optimistic about the continuation of the Hong Kong stock market's performance in the second half of the year, citing a stable economic recovery and the potential for more quality companies to list in Hong Kong [3] - The ongoing deepening of the mutual market access mechanism between mainland China and Hong Kong is expected to attract more southbound capital, providing long-term and stable funding support for the market [3] Group 3 - The Hong Kong stock market is positioned as a frontier for the integration of Chinese industries and global capital, attracting international investors due to its stable domestic environment and strong economic resilience [4] - The current global political and economic uncertainties have increased investor interest in assets with higher certainty, making the Hong Kong market an attractive option for international capital [4]

Group 1 - In the first eight months of the year, 610 out of 644 comparable QDII funds saw an increase in net value, representing 94.7% of the total [1] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers including Huatai-PB Hong Kong Advantage Selected Mixed C and A, achieving returns of 133.73% and 133.56% respectively [1] - The top ten holdings of Huatai-PB Hong Kong Advantage Selected Mixed A/C include companies such as InnoCare Pharma, Kelun-Biotech, and Innovent Biologics [1] Group 2 - Ten QDII funds recorded gains exceeding 90%, with four from E Fund Management, including E Fund Global Pharmaceutical Industry Mixed Fund, all surpassing 94% [2] - The top ten holdings of these E Fund products include major players like Innovent Biologics and InnoCare Pharma [2] Group 3 - Funds such as GF CSI Hong Kong Innovative Drug ETF and Huatai-PB Hang Seng Innovative Drug ETF also performed well, with returns of 103.70% and 100.04% respectively [3] - The top ten holdings of the larger Huatai-PB Hang Seng Biotechnology ETF include companies like Innovent Biologics and WuXi Biologics [3] Group 4 - The bottom performers among QDII funds primarily tracked the FTSE Saudi Arabia Index, with several oil and gas funds and those tracking the S&P 500 healthcare index also underperforming [4]

Core Insights - In the first seven months of the year, 600 out of 650 comparable QDII funds saw an increase in net value, representing a 92.31% success rate [1] - The innovation drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top-performing funds achieving returns exceeding 137% [1] - Several QDII funds, particularly those managed by E Fund, reported increases of over 90%, with four funds exceeding 95% returns, all focused on the innovative drug industry [2] Group 1: Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hang Seng Innovation Drug ETF and others, with returns ranging from 100.48% to 87.44%, attributed to the strong performance of the innovation drug sector [3] - The leading QDII funds, such as Huatai-PineBridge and E Fund, have concentrated their investments in key innovative drug companies, including Innovent Biologics and Sinopharm [2][3] Group 2: Fund Management - The fund manager for the top-performing Huatai-PineBridge funds is Zhao Bei, who has been with the company since 2010 and currently leads the healthcare research team [3] - Zhang Wei, the manager of the top-performing Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund, has a background in pharmaceutical research and has held various roles in the industry [1]

Group 1 - In July 2023, 670 comparable QDII funds were analyzed, with 586 funds (87.46%) showing an increase in net value, while 80 funds experienced a decline, and 4 funds remained flat [1] - 15 QDII funds had a monthly increase exceeding 24%, with the top performers being E Fund Global Healthcare Mixed Fund (QDII) C (USD) at 28.94%, followed closely by other E Fund variants [1] - The E Fund Global Healthcare Mixed Fund (QDII) C (USD) was established on November 15, 2023, while its A share (USD) was launched on January 20, 2020 [1] Group 2 - As of July 31, 2025, the year-to-date returns for the top E Fund variants were 97.18%, 96.71%, 96.05%, and 95.63%, with cumulative net values ranging from 0.1956 to 1.4089 [2] - The fund maintained a positive outlook on the Chinese pharmaceutical industry, particularly focusing on innovative drug companies, and optimized stock selection as of the second quarter [2] - The largest fund by size among the top performers was the GF CSI Hong Kong Innovative Drug ETF, with a scale of 15.9 billion yuan and a July increase of 27.04% [2] Group 3 - The Manulife India Equity Fund (QDII), established on January 30, 2019, reported a year-to-date return of -2.38% and a cumulative net value of 1.5203 yuan as of July 31, 2025 [3] - The fund's investment strategy shifted from strong defensive positions to include more mid-cap companies and sectors like public utilities and new consumption [3] - The top ten holdings of the Manulife India Equity Fund included major companies such as Reliance Industries and HDFC Bank as of the second quarter [3]

Core Insights - 华夏基金（香港） has been focusing on innovative financial products and positioning itself as a differentiated Chinese institution in the market [1][3] - The CEO, 甘添, believes that the new technology revolution is reshaping the financial industry, providing strategic opportunities for asset management institutions in Hong Kong [1][3] - The offshore RMB bond market is expected to experience explosive growth in the next three to five years, with 华夏香港 already taking the lead in this area [1][5] Company Strategy - 华夏香港 has launched several innovative products, including the first RMB-denominated public fund in Hong Kong and the largest offshore RMB money market ETF, which has grown to a scale of 4.97 billion RMB within two years [3][4] - The company has also introduced the first pure Hong Kong stock biotech ETF and the largest ESG broad-based ETF in Asia (excluding Japan), showcasing its commitment to differentiation in the ETF market [4] Market Outlook - 甘添 predicts that the offshore RMB funds pool could reach approximately 5 trillion RMB by 2030, driven by the internationalization of the RMB and the growth of the dim sum bond market [6][8] - The dim sum bond market has seen significant growth, with the market size increasing from 254 billion RMB in 2020 to nearly 1 trillion RMB currently, indicating a strong demand for these bonds [6][7] Investment Trends - The yield on dim sum bonds is currently more attractive compared to domestic bonds, leading to increased interest from domestic investors facing asset allocation challenges [7][8] - Major domestic enterprises are increasingly using dim sum bonds to replace USD-denominated bonds, reflecting a shift in financing strategies [7][8] Regulatory Environment - The Chinese government is actively supporting the internationalization of the RMB, which is expected to enhance the development of the offshore RMB market [6][8] - Recent policy optimizations, such as the cross-border wealth management connect, are facilitating domestic investors' access to offshore RMB assets, providing a stable funding source for the offshore market [8][9]